Literature DB >> 29116255

Prostate cancer: No benefit of combining custirsen with cabazitaxel.

Clemens Thoma.   

Abstract

Entities:  

Year:  2017        PMID： 29116255     DOI： 10.1038/nrurol.2017.193

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

Authors:  Tomasz M Beer; Sebastien J Hotte; Fred Saad; Boris Alekseev; Vsevolod Matveev; Aude Fléchon; Gwenaelle Gravis; Florence Joly; Kim N Chi; Zafar Malik; Brent Blumenstein; Patricia S Stewart; Cindy A Jacobs; Karim Fizazi
Journal:  Lancet Oncol       Date:  2017-10-09       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.